A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

Más betegség

• Diagnosed with Type 1 diabetes mellitus.

Egyéb

• Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
• Known pregnancy at the time of visit or having the intention to become pregnant.

• Participants must be ≥ 18 years of age at the time of signing the ICF.
• Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
  • Health Organization or local diagnostic standards, inadequately managed with:
• Lifestyle management alone, AND/OR
• A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
  • Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
  • Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.